Providing a diverse range of perspectives from bullish to bearish, 7 analysts have published ratings on Boston Scientific BSX in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 4 | 2 | 0 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $108.14, along with a high estimate of $119.00 and a low estimate of $100.00. Marking an increase of 8.91%, the current average surpasses the previous average price target of $99.29.
Deciphering Analyst Ratings: An In-Depth Analysis
In examining recent analyst actions, we gain insights into how financial experts perceive Boston Scientific. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jayson Bedford | Raymond James | Raises | Strong Buy | $119.00 | $101.00 |
| Richard Newitter | Truist Securities | Raises | Buy | $110.00 | $100.00 |
| Robbie Marcus | JP Morgan | Raises | Overweight | $110.00 | $100.00 |
| Joshua Jennings | TD Cowen | Raises | Buy | $110.00 | $100.00 |
| Joanne Wuensch | Citigroup | Raises | Buy | $107.00 | $98.00 |
| Larry Biegelsen | Wells Fargo | Raises | Overweight | $100.00 | $98.00 |
| William Plovanic | Canaccord Genuity | Raises | Buy | $101.00 | $98.00 |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Boston Scientific. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Boston Scientific compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Boston Scientific's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Boston Scientific's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Boston Scientific analyst ratings.
About Boston Scientific
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Understanding the Numbers: Boston Scientific's Finances
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Boston Scientific's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 19.34%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Boston Scientific's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 11.14%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Boston Scientific's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.28%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Boston Scientific's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.25%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Boston Scientific's debt-to-equity ratio is below the industry average. With a ratio of 0.54, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
